ArticleACR open rheumatology2026
Clinical Associations of Anti-RNPC3 Autoantibodies in Mixed Connective Tissue Disease.
Article in ACR open rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectiveThe RNA-binding region-containing protein 3 (RNPC3) protein acts as a molecular bridge, promoting U11/U12 RNP complex formation. In previous reports, patients with systemic sclerosis (SSc) with anti-RNPC3 autoantibodies had an increased risk of interstitial lung disease (ILD), severe gastrointestinal (GI) disease, and cancer. The aim of this study was to compare phenotypic features of patients with mixed connective tissue disease (MCTD) with and without anti-RNPC3 autoantibodies.
methodsA retrospective MCTD cohort was studied. Addressable laser bead immunoassay was used to detect anti-RNPC3 autoantibodies with <1,000 mean fluorescence intensity (MFI) as normal reference range, 1,000 to 2,999 MFI as low-titer positivity and ≥3,000 MFI as high-titer positivity. Cancer occurrence within (±) five years of MCTD diagnosis and comparison of clinical features between anti-RNPC3+ and anti-RNPC3- subgroups were analyzed.
resultsFifteen of 66 (23%) patients with MCTD were anti-RNPC3+, which were associated with a higher frequency of sclerodactyly (anti-RNPC3+ vs anti-RNPC3-: 100% vs 67%, P = 0.007), but their frequency in ILD and GI involvement was similar (4 of 12, 33% vs 18 of 44, 41%, P = 0.73; and 13 of 14, 93% vs 43 of 46, 93% P = 0.91, respectively). Cancer was present in 3 of 15 (20%) anti-RNPC3+ compared to 3 of 51 (5.9%) anti-RNPC3- patients (P = 0.13). Numerically, more malignancy was observed among patients with high-titer anti-RNPC3+ (unadjusted odds ratio 16.00, 95% confidence interval 0.54-484.28, P = 0.07).
conclusionAnti-RNPC3 autoantibodies were associated with a higher frequency of SSc skin involvement in patients with MCTD. Anti-RNPC3 autoantibodies, especially in high titers, might be the markers for an increased risk of cancer in MCTD that needs to be confirmed in larger cohorts.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.